Skip to content

Pharminent

cropped-neurology_aaic_banner_frontpage_2026-07-15-1.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Regulatory
  • Pazdur declines to announce candidacy for vacated FDA commissioner role
  • Regulatory

Pazdur declines to announce candidacy for vacated FDA commissioner role

BioSpace

FDA veteran Richard Pazdur outlined his priorities for the next FDA commissioner but stopped short of putting himself forward as a candidate to lead the agency at an RBC Capital Markets event on Tuesd

Read full story

pharminent May 20, 2026 (Last updated: May 20, 2026)

BioSpace

FDA veteran Richard Pazdur outlined his priorities for the next FDA commissioner but stopped short of putting himself forward as a candidate to lead the agency at an RBC Capital Markets event on Tuesd

Read full story

Post navigation

Previous: Pepaxti study supports use in wider myeloma population
Next: Immunovant’s potential autoimmune ‘blockbuster’; Wave’s RNA editing update

Related Stories

  • Regulatory

Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa

pharminent August 20, 2026
  • Regulatory

Regeneron wins FDA approval to challenge Ipsen for rare bone disease market

pharminent August 20, 2026
  • Regulatory

FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy

pharminent August 20, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.